ALFACARE is a health activation and emotional support program aimed at patients with COPD due to alpha-1 antitrypsin deficiency (AATD) undergoing treatment with intravenous alpha-1 antitrypsin (AATD). Alfacare Program 2019 It is a pioneering program in activating the patient from home It has been designed to complement usual clinical care and treatment. The objectives of
Alfacare Program 2019 Read More »
An editorial has recently been published in the Archives of Bronchopneumology that analyzes the differences between the approved treatments for the treatment of pulmonary emphysema due to Alpha-1 deficiency. Esquinas C, Miravitlles M. Arch Bronconeumol. 2018;54:451-452. This publication reflects the differences between the approved treatments for pulmonary emphysema due to Alpha-1 atitrypsin deficiency in Spain,
Food is the basis of a healthy life. Adopting good habits will help us maintain and / or achieve our healthy weight and feel stronger. Download healthy guide
Alphas Camino de Santiago 2018 Healthy Eating Guide Read More »
The Alpha-1 Association of Spain, of patients and families affected by Alpha-1 Antitrypsin Deficit, organizes the Alfas en Camino 2018 program the last week of August 2018. They will cover a total of 115 kilometers on foot, from the town of Sarria, in the province of Lugo, to Santiago de Compostela. Our call is especially
Alpha-1 Center on the Camino de Santiago Read More »
The Alfa-1 Centers in Granada and Seville have collaborated with Alfa-1 Spain in the DAAT update meetings in Andalusia. Read more Download program
Alfa-1 Spain organizes two update meetings on the AATD in Andalusia Read More »
On this occasion, two meetings will be held in Andalusia to update knowledge about the Alpha-1 Antitrypsin Deficit next May. It has the collaboration of the Alfa-1 Center of Andalusia in Granada and Seville, as well as REDAAT. You can find more information on the following button: Read more
A study has been published that analyzes the role of primary care physicians in the diagnosis of AATD in the USA. This is a review that analyzes the underdiagnosis of COPD and AATD among primary care physicians in the United States. It is estimated that less than 10% of symptomatic AATD patients are diagnosed in
Study on the role of doctors in the diagnosis of AATD Read More »
In this study the prevalence of the Pi * SZ genotype is estimated worldwide, statistics in studies of previous populations. 262 cohorts from 71 countries are included for analysis. The allowed data from these cohorts allow estimating the existence of almost 1,500,000 Pi * SZ individuals worldwide, the majority (48%) in Europe, 39% in America
Download document In January 2017, more than 30 organizations presented this document of proposals with the aim of establishing active and permanent platforms that jointly enable effective solutions to be found between the competent public authorities, political representatives and all the groups belonging to the field. of rare, minority or infrequent diseases and, thus, be
Recommendations for the search for solutions in the field of Rare Diseases Read More »
Ph. Francisco Casas talks to Pilar Carballada about his COPD as a result of Alpha-1 Antitrypsin Deficiency, difficulty in diagnosis, treatment, and his current feeling about tobacco after being a smoker.
Talking to my pulmonologist, Doctor Francisco Casas with Pilar Carballada Read More »
